company background image
RGBP

Regen BioPharma OTCPK:RGBP Stock Report

Last Price

US$0.0045

Market Cap

US$22.7m

7D

-2.2%

1Y

-55.7%

Updated

24 Jan, 2023

Data

Company Financials

RGBP Stock Overview

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States.

RGBP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health0/6
Dividends0/6

My Notes

New

Notes are coming soon

Regen BioPharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regen BioPharma
Historical stock prices
Current Share PriceUS$0.0045
52 Week HighUS$0.015
52 Week LowUS$0.0034
Beta3.39
1 Month Change9.76%
3 Month Change-18.18%
1 Year Change-55.67%
3 Year Change4,400.00%
5 Year Change-89.53%
Change since IPO-98.82%

Recent News & Updates

Recent updates

Shareholder Returns

RGBPUS BiotechsUS Market
7D-2.2%-0.7%1.0%
1Y-55.7%7.2%-9.6%

Return vs Industry: RGBP underperformed the US Biotechs industry which returned 7% over the past year.

Return vs Market: RGBP underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is RGBP's price volatile compared to industry and market?
RGBP volatility
RGBP Average Weekly Movement13.5%
Biotechs Industry Average Movement12.2%
Market Average Movement7.1%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: RGBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: RGBP's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20121David Kooshttps://regenbiopharmainc.com

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is also involved in the development of its products, and therapies, including HemaXellarate, a cellular composition of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.

Regen BioPharma, Inc. Fundamentals Summary

How do Regen BioPharma's earnings and revenue compare to its market cap?
RGBP fundamental statistics
Market CapUS$22.72m
Earnings (TTM)US$1.22m
Revenue (TTM)US$235.52k

18.7x

P/E Ratio

96.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGBP income statement (TTM)
RevenueUS$235.52k
Cost of RevenueUS$0
Gross ProfitUS$235.52k
Other Expenses-US$982.27k
EarningsUS$1.22m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.00024
Gross Margin100.00%
Net Profit Margin517.07%
Debt/Equity Ratio-10.5%

How did RGBP perform over the long term?

See historical performance and comparison